Q4 2025 Arcturus Therapeutics Holdings Inc Earnings Call Transcript
Key Points
- ARCTO 32 phase 2 trial is progressing with no safety concerns at higher doses, indicating a positive safety profile.
- The UK MHRA granted approval for Costave, a self-amplifying mRNA COVID-19 vaccine, marking a regulatory milestone.
- ARCT 2,304 vaccine candidate for pandemic influenza showed durable immune response and was well tolerated in phase one study.
- Arcturus Therapeutics Holdings Inc (ARCT) has extended its cash runway into the second quarter of 2028, indicating strong financial management.
- The company is actively engaging with regulatory authorities to clarify the clinical development strategy for its OTC deficiency program, showing proactive regulatory engagement.
- Year-over-year revenue decreased by $70.3 million annually and $15.6 million quarterly, reflecting reduced collaboration and milestone achievements.
- Research and development expenses decreased significantly, indicating potential scaling back of certain programs.
- General and administrative expenses increased quarterly due to accelerated employee stock options, impacting cost management.
- The lawsuit against Abvi and Capston Therapeutics remains ongoing, posing potential legal and financial risks.
- The commercialization of Costave in the US faces challenges due to the current domestic administration, affecting potential revenue streams.
Hello and welcome everyone joining today's Arcturus Therapeutics fourth quarter in fiscal year 2025 earnings call. (Operator Instructions) Please note this call is being recorded. We are standing by if you should need any assistance, and it is now my pleasure to turn the meeting over to Netta Seffarzadeh, Vice President, head of Investor relations, public relations, and marketing. Please go ahead.
Thank you, operator. Good afternoon and welcome to Arc Terrace Therapeutics quarterly financial update and pipeline for call. Today's call will be led by Joe Payne, our President and CEO, and Doctor Alan Cohen, our Chief Medical Officer. Dr. Pathibecula, our CSO and COO, will join them for the Q&A session.
Before we begin, I would like to remind everyone that the statements made during this call regarding matters that are not historical facts are forward-looking statements within the safe harbor provisions of the Private
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
